Eptinezumab's Cost-Effectiveness for Migraine Relief in Taiwan

Research Summary

A new study published in Health Economics Review evaluates the cost-effectiveness of eptinezumab, a calcitonin gene-related peptide inhibitor, for preventing migraines in Taiwan. Using a Markov model over six months, researchers compared eptinezumab to a placebo from a health payer's perspective. The analysis revealed that eptinezumab costs $4,461 with a QALY of 0.35, while placebo costs $1,065 with a QALY of 0.31, resulting in an ICER of $73,929 per QALY gained. While eptinezumab is cost-effective in 98% of scenarios at three times Taiwan's GDP per capita, utility values based on migraine frequency are crucial for future evaluations.

Study Details

📄 Title: Cost-utility analysis of eptinezumab for migraine prevention in Taiwan.

👥 Research Team: Chan CS et al.

📚 Published In: Health Econ Rev

📅 Publication Date: 2025 Dec 28

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.